Considering that Tregs from colorectal or nonsmall‐cell lung cancers express high level of IL1R2 mRNA and protein35 and that the binding of PD‐L1 to PD‐1 reduces apoptosis in Treg cells,36 neutralizing antibodies to IL1R2 combined with an inhibitor of immune‐checkpoint receptors may also be a potential new therapeutic strategy for BC. The gene discussed is IL1R2; the disease is breast cancer.